» Articles » PMID: 3532975

Evaluation of Insulin Secretion After Pancreas Autotransplantation by Oral or Intravenous Glucose Challenge

Overview
Journal Ann Surg
Specialty General Surgery
Date 1986 Nov 1
PMID 3532975
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Segmental pancreatic autotransplantation is accompanied by surgical alterations to the pancreas that may have consequences for carbohydrate metabolism. Four mongrel dogs were evaluated before operation and sequentially until 40 weeks after total pancreatectomy and autotransplantation of the splenic lobe of the pancreas with bolus intravenous and oral administration. Intravenous glucose tolerance test (IVGTT) (0.5 g/kg) revealed maintenance of fasting euglycemia for as long as 40 weeks after operation. Peak glucose and integrated glucose values did not show significant changes as a result of autotransplantation. Following transplantation, a delayed peak insulin response was seen; however, basal, peak, and integrated insulin values were largely unaltered. Only K values, a measure of glucose disposal, showed severe alterations (2.44 +/- 0.21 before operation to 1.24 +/- 0.30 at 40 weeks after operation). Oral glucose tolerance tests (OGTT) (2.0 g/kg) demonstrated an increased peak hyperglycemic response after autotransplantation with increased integrated glucose responses. Insulin levels remained at those levels seen before operation, and glucose-dependent insulinotropic polypeptide (GIP) responses were unchanged during the OGTT as late as 20 weeks after operation. In conclusion, pancreas autotransplantation after total pancreatectomy results in significant metabolic alterations that the IVGTT fails to detect with absolute glucose or insulin levels. However, K values are significantly lowered, which indicates alterations in cellular glucose transport. The OGTT demonstrates hyperglycemia without increased insulin or GIP levels, which suggests an altered beta cell response to the enteric stimulus of insulin release. These changes are nonetheless well tolerated by animals that have remained clinically healthy and euglycemic in the basal state.

Citing Articles

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.

Plamboeck A, Veedfald S, Deacon C, Hartmann B, Wettergren A, Svendsen L Eur J Endocrinol. 2013; 169(2):187-201.

PMID: 23704713 PMC: 3709640. DOI: 10.1530/EJE-13-0264.


Pancreatic structure and glucose tolerance in a longitudinal study of experimental pancreatitis-induced diabetes.

Yeo C, Bastidas J, Schmieg Jr R, Walfisch S, Couse N, Olson J Ann Surg. 1989; 210(2):150-8.

PMID: 2474267 PMC: 1357820. DOI: 10.1097/00000658-198908000-00003.


Glucose metabolism after pancreas autotransplantation. The effect of open duct versus urinary bladder drainage technique.

Barone G, FLANAGAN T, Cornett G, Pruett T, Hanks J Ann Surg. 1991; 213(2):159-65.

PMID: 1992943 PMC: 1358389. DOI: 10.1097/00000658-199102000-00011.


Pancreas transplantation. An initial experience with systemic and portal drainage of pancreatic allografts.

Rosenlof L, Earnhardt R, Pruett T, Stevenson W, Douglas M, Cornett G Ann Surg. 1992; 215(6):586-95; discussion 596-7.

PMID: 1632680 PMC: 1242509. DOI: 10.1097/00000658-199206000-00005.

References
1.
PERLEY M, KIPNIS D . Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967; 46(12):1954-62. PMC: 292948. DOI: 10.1172/JCI105685. View

2.
Brown J, Dryburgh J, Ross S, Dupre J . Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res. 1975; 31:487-532. DOI: 10.1016/b978-0-12-571131-9.50017-7. View

3.
Andersen D, Elahi D, Brown J, Tobin J, Andres R . Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest. 1978; 62(1):152-61. PMC: 371748. DOI: 10.1172/JCI109100. View

4.
Strubbe J . Effects of pancreas transplantation on insulin secretion in the rat during ingestion of varying glucose loads. Diabetologia. 1982; 22(5):354-7. DOI: 10.1007/BF00253581. View

5.
Brown J, PEDERSON R, JORPES E, Mutt V . Preparation of highly active enterogastrone. Can J Physiol Pharmacol. 1969; 47(1):113-4. DOI: 10.1139/y69-020. View